BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 18819092)

  • 1. Hemostatic complications of angiogenesis inhibitors in cancer patients.
    Elice F; Jacoub J; Rickles FR; Falanga A; Rodeghiero F
    Am J Hematol; 2008 Nov; 83(11):862-70. PubMed ID: 18819092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic events in patients with cancer receiving antiangiogenesis agents.
    Zangari M; Fink LM; Elice F; Zhan F; Adcock DM; Tricot GJ
    J Clin Oncol; 2009 Oct; 27(29):4865-73. PubMed ID: 19704059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombosis associated with angiogenesis inhibitors.
    Elice F; Rodeghiero F; Falanga A; Rickles FR
    Best Pract Res Clin Haematol; 2009 Mar; 22(1):115-28. PubMed ID: 19285278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complications from vascular disrupting agents and angiogenesis inhibitors: aberrant control of hemostasis and thrombosis.
    van Heeckeren WJ; Sanborn SL; Narayan A; Cooney MM; McCrae KR; Schmaier AH; Remick SC
    Curr Opin Hematol; 2007 Sep; 14(5):468-80. PubMed ID: 17934353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bleeding complications of antiangiogenic therapy: pathogenetic mechanisms and clinical impact.
    Elice F; Rodeghiero F
    Thromb Res; 2010 Apr; 125 Suppl 2():S55-7. PubMed ID: 20434006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenesis as a therapeutic target.
    Ferrara N; Kerbel RS
    Nature; 2005 Dec; 438(7070):967-74. PubMed ID: 16355214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic determinants of cancer coagulopathy, angiogenesis and disease progression.
    Rak J; Klement P; Yu J
    Vnitr Lek; 2006 Mar; 52 Suppl 1():135-8. PubMed ID: 16637463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of the hemostatic system to angiogenesis in cancer.
    Wojtukiewicz MZ; Sierko E; Rak J
    Semin Thromb Hemost; 2004 Feb; 30(1):5-20. PubMed ID: 15034794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of angiogenesis in the treatment of tumors.
    Ostrowski K; Kinsner A
    Arch Immunol Ther Exp (Warsz); 2001; 49(1):27-31. PubMed ID: 11266087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular mechanisms and therapeutic development of angiogenesis inhibitors.
    Cao Y
    Adv Cancer Res; 2008; 100():113-31. PubMed ID: 18620094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Angiogenesis inhibitors in advanced cancer. Many current clinical trials show promising results].
    Christofferson R
    Lakartidningen; 1998 May; 95(20):2349-54. PubMed ID: 9630803
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiogenesis and cancer: recent advances.
    Cáceres W; González S
    P R Health Sci J; 2003 Jun; 22(2):149-51. PubMed ID: 12866139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
    Kerbel RS
    Science; 2006 May; 312(5777):1171-5. PubMed ID: 16728631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancer.
    Ademuyiwa FO; Miller KD
    Clin Breast Cancer; 2008 Dec; 8 Suppl 4():S151-6. PubMed ID: 19158035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thromboembolic risk associated with use of angiogenesis inhibitors used for the treatment of cancers].
    Drouet L
    Pathol Biol (Paris); 2008 Jun; 56(4):195-204. PubMed ID: 18450388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cancer chemotherapy and anticoagulant prophylaxis].
    Blaskó G
    Magy Onkol; 2008 Jun; 52(2):193-9. PubMed ID: 18640896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of hemostatic system inhibitors in malignancy.
    Wojtukiewicz MZ; Sierko E; Kisiel W
    Semin Thromb Hemost; 2007 Oct; 33(7):621-42. PubMed ID: 18000789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The interaction of radiation therapy and antiangiogenic therapy.
    O'Reilly MS
    Cancer J; 2008; 14(4):207-13. PubMed ID: 18677126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumour vascularisation: a druggable target.
    Bishop-Bailey D
    Curr Opin Pharmacol; 2009 Apr; 9(2):96-101. PubMed ID: 19056315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interfering with hemostatic system components: possible new approaches to antiangiogenic therapy.
    Wojtukiewicz MZ; Sierko E; Zacharski LR
    Semin Thromb Hemost; 2004 Feb; 30(1):145-56. PubMed ID: 15034806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.